Profile
Mr. Peter A. Coleman is a Chief Executive Officer at Roslin Cell Therapies Ltd., a Chief Executive Officer & Director at Cobra Biologics Ltd. and a Secretary & Finance Director at Cobra Biologics Holdings Ltd. He is on the Board of Directors at Cobra Biologics Ltd. Mr. Coleman was previously employed as a Chief Executive Officer & Director by Cobra Biologics Holding AB.
Peter Coleman active positions
| Companies | Position | Start |
|---|---|---|
Cobra Biologics Holdings Ltd.
Cobra Biologics Holdings Ltd. BiotechnologyHealth Technology Manufactures biopharmaceutical products | Director of Finance/CFO | 2009-05-13 |
Cobra Biologics Ltd.
Cobra Biologics Ltd. Pharmaceuticals: MajorHealth Technology Engages in development of DNA-based technologies, services and products | Chief Executive Officer | 2011-04-30 |
Roslin Cell Therapies Ltd.
Roslin Cell Therapies Ltd. BiotechnologyHealth Technology Develops and manufactures cell and gene therapeutics | Chief Executive Officer | 2022-02-28 |
Former positions of Peter Coleman
| Companies | Position | End |
|---|---|---|
Cobra Biologics Holding AB
Cobra Biologics Holding AB Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Chief Executive Officer | - |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 4 |
|---|---|
Cobra Biologics Holdings Ltd.
Cobra Biologics Holdings Ltd. BiotechnologyHealth Technology Manufactures biopharmaceutical products | Health Technology |
Cobra Biologics Ltd.
Cobra Biologics Ltd. Pharmaceuticals: MajorHealth Technology Engages in development of DNA-based technologies, services and products | Health Technology |
Cobra Biologics Holding AB
Cobra Biologics Holding AB Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Roslin Cell Therapies Ltd.
Roslin Cell Therapies Ltd. BiotechnologyHealth Technology Develops and manufactures cell and gene therapeutics | Health Technology |
- Stock Market
- Insiders
- Peter Coleman
















